Author: Gábor Cserni1,2
View More View Less
  • 1 Bács-Kiskun Megyei Kórház, 6000 Kecskemét, Nyíri út 38.
  • | 2 Szegedi Tudományegyetem, Szeged
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $356.00

Absztrakt

Az őrszemnyirokcsomó-biopszia bevezetése lényegesen megváltoztatta az emlőrákos betegek axillájának hagyományos, hónalji blokkdissectióval történő kezelését, és napjainkra sokkal árnyaltabbá tette azt. Azt, hogy a korai emlőrákos betegek közül kinél kell őrszemnyirokcsomó-biopsziát végezni és kinél kell e helyett vagy ez után hónalji blokkdissectiót alkalmazni, több paraméter befolyásolja. A lehetséges opciókat a közlemény egy algoritmus formájában foglalja össze, és ennek az algoritmusnak az egyes elemeit magyarázza, az ezzel kapcsolatos legfontosabb ismeretanyagot foglalja össze.

  • 1

    Cserni G: Őrszemnyirokcsomó-státusz és hónalji blokkdissectio az emlőrák sebészi ellátásában. Orv Hetil 2014; 155: 203–215

  • 2

    Sobin L, Gospodarowicz M, Wittekind Ch (eds.): UICC TNM classification of malignant tumours, 7th edition. John Wiley and Sons Inc., New York, 2009

  • 3

    Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bussolati G, Connolly CE, Cserni G, Decker T, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Nordgren H, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafrani B, Tanous AM, Thorstenson S, Zozaya E, Wells CA: Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edition. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds.). European Comission, Luxemburg, 2006, 219–311

  • 4

    Cserni G, Francz M, Járay B, Kálmán E, Kovács I, Kulka J, Orosz Zs, Udvarhelyi N, Vass L: Az emlőrák patológiai diagnosztikája, feldolgozása és kórszövettani leletezése. Magy Onkol 2010; 54: 217–226

  • 5

    Giuliano AE, Morrow M, Duggal S, Julian TB: Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012; 29: 687–692

  • 6

    Castellano I, Deambrogio C, Muscarà F, Chiusa L, Mariscotti G, Bussone R, Gazzetta G, Macrì L, Cassoni P, Sapino A: Efficiency of a preoperative axillary ultrasound and fine-needle aspiration cytology to detect patients with extensive axillary lymph node involvement. PLoS One 2014; 9: e1066406

  • 7

    Robertson IJ, Hand F, Kell MR: FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast 2011; 20: 491–494

  • 8

    Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; ESMO Guidelines Committee: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 6): vi7–vi23

  • 9

    Zgajnar J, Hocevar M, Podkrajsek M, Hertl K, Frkovic-Grazio S, Vidmar G, Besic N: Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early breast cancer patients. Breast Cancer Res Treat 2006; 97: 293–299

  • 10

    Specht MC, Fey JV, Borgen PI, Cody HS 3rd: Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy? J Am Coll Surg 2005; 200: 10–14

  • 11

    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319–1329

  • 12

    AGO, DGS, SGS, ÖGS, Panelists, Executive Board Members; Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F: German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer. Eur J Cancer 2013; 49: 2277–2283

  • 13

    Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB 3rd, Bosserman LD, Burstein HJ, Cody H 3rd, Hayman J, Perkins CL, Podoloff DA, Giuliano AE: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32: 1365–1383

  • 14

    NCCN: Clinical practice guidelines in oncology, Breast cancer, version 3.2015 http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed: 22 October 2015

  • 15

    Douek M, Klaase J, Monypenny I, Kothari A, Zechmeister K, Brown D, Wyld L, Drew P, Garmo H, Agbaje O, Pankhurst Q, Anninga B, Grootendorst M, Ten Haken B, Hall-Craggs MA, Purushotham A, Pinder S; SentiMAG Trialists Group: Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol 2014; 21: 1237–1245

  • 16

    Thill M, Kurylcio A, Welter R, van Haasteren V, Grosse B, Berclaz G, Polkowski W, Hauser N: The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 2014; 23: 175–179

  • 17

    Cody HS 3rd, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, Yeh SD, Borgen PI: Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol 2001; 8: 13–19

  • 18

    Derossis AM, Fey J, Yeung H, Yeh SD, Heerdt AS, Petrek J, VanZee KJ, Montgomery LL, Borgen PI, Cody HS 3rd: A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001; 193: 473–478

  • 19

    Sadeghi R, Alesheikh G, Zakavi SR, Fattahi A, Abdollahi A, Assadi M, Jangjoo A, Keshtgar M: Added value of blue dye injection in sentinel node biopsy of breast cancer patients: do all patients need blue dye? Int J Surg 2014; 12: 325–328

  • 20

    OʼReilly EA, Prichard RS, Al Azawi D, Aucharaz N, Kelly G, Evoy D, Geraghty J, Rothwell J, OʼDoherty A, Quinn C, Skehan SJ, McDermott EW: The value of isosulfan blue dye in addition to isotope scanning in the identification of the sentinel lymph node in breast cancer patients with a positive lymphoscintigraphy: a randomized controlled trial (ISRCTN98849733). Ann Surg Oncol 2015; 262: 243–248

  • 21

    Ahmed M, Purushotham AD, Horgan K, Klaase JM, Douek M: Meta-analysis of superficial versus deep injection of radioactive tracer and blue dye for lymphatic mapping and detection of sentinel lymph nodes in breast cancer. Br J Surg 2015; 102: 169–181

  • 22

    Cserni G: Az őrszemnyirokcsomók elmélete emlőrákban. Magyar Tudomány 2004; 111: 718–722

  • 23

    Galimberti V, Manika A, Maisonneuve P, Corso G, Salazar Moltrasio L, Intra M, Gentilini O, Veronesi P, Pagani G, Rossi E, Bottiglieri L, Viale G, Rotmensz N, De Cicco C, Grana CM, Sangalli C, Luini A: Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. Eur J Surg Oncol 2014; 40: 1203–1208

  • 24

    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11: 927–933

  • 25

    Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE: Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg 2012; 256: 428–436

  • 26

    Petrelli F, Lonati V, Barni S: Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follow up. Oncol Rev 2012; 6: e20

  • 27

    Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604–1608

  • 28

    Cserni G, Amendoeira I, Bianchi S, Chmielik E, Degaetano J, Faverly D, Figueiredo P, Foschini MP, Grabau D, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Penuela JM, Quinn C, Regitnig P, Reiner-Concin A, Sapino A, van Diest PJ, Varga Z, Vezzosi V, Wesseling J, Zolota V, Zozaya E, Wells CA: Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. Eur J Cancer 2011; 47: 887–894

  • 29

    Van Deurzen CH, de Boer M, Monninkhof EM, Bult P, van der Wall E, Tjan-Heijnen VC, van Diest PJ: Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J Natl Cancer Inst 2008; 100: 1574–1580

  • 30

    Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, Sandrucci S, Baltás B, Bussolati G: Non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer: metaanalysis of 25 studies. Br J Surg 2004; 91: 1245–1252

  • 31

    Clarke D, Newcombe RG, Mansel RE; ALMANAC Trialists Group: The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol 2004; 11(3 Suppl): 211S–215S

  • 32

    Mansel RE, MacNeill F, Horgan K, Goyal A, Britten A, Townson J, Clarke D, Newcombe RG, Keshtgar M; Guildford Breast Surgeons; New Start Training Group, Kissin M, Layer G, Hilson A, Ell P, Wishart G, Brown D, West N: Results of a national training programme in sentinel lymph node biopsy for breast cancer. Br J Surg 2013; 100: 654–661

  • 33

    Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703–7720

  • 34

    Péley G: Radioizotópos sebészeti lehetőségek a korai emlőrák kezelésében. PhD-értekezés, Semmelweis Egyetem Doktori Iskola, Budapest, 2005, p. 145. http://phd.semmelweis.hu/mwp/phd_live/vedes/export/peleygabor.d.pdf Accessed: 22 October 2015

  • 35

    Forrest APM, Everington D, McDonald CC, Steele RJ, Chetty U, Stewart HJ: The Edinburgh randomised trial of axillary sampling or clearance after mastectomy. Br J Surg 1995; 82: 1504–1508

  • 36

    Chetty U, Jack W, Prescott RJ, Tyler C, Rodger A: Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Edinburgh Breast Unit. Br J Surg 2000; 87: 163–169

  • 37

    Ahlgren J, Holmberg L, Bergh J, Liljegren G: Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol 2002; 28: 97–102

  • 38

    Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE: Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95: 279–293

  • 39

    Rutgers EJ, Nieweg OE: Finding lymph node metastases in invasive breast cancer: sampling or sentinel node procedure? Eur J Surg Oncol 2002; 28: 569–567

  • 40

    Macmillan RD, Barbera D, Hadjiminas DJ, Rampaul RS, Lee AH, Pinder SE, Ellis IO, Blamey RW, Geraghty JG: Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. Eur J Cancer 2001; 37: 1076–1080

  • 41

    Sato K, Tamaki K, Takeuchi H, Tsuda H, Kosuda S, Kusano S, Hiraide H, Mochizuki H: Management of the axilla in breast cancer: a comparative study between sentinel lymph node biopsy and four-node sampling procedure. Jpn J Clin Oncol 2001; 31: 318–321

  • 42

    Agarwal T, Kakkos SK, Cunningham DA, Darzi A, Lee D, Rajan P, Hadjiminas DJ: Sentinel node biopsy can replace four-node-sampling in staging early breast cancer. Eur J Surg Oncol 2005; 31: 122–127

  • 43

    Nieweg OE, Estourgie SH: What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol 2004; 11(3 Suppl): 169S–173S

  • 44

    Choi YJ, Kim JH, Nam SJ, Ko YH, Yang JH: Intraoperative identification of suspicious palpable lymph nodes as an integral part of sentinel node biopsy in patients with breast cancer. Surg Today 2008; 38: 390–394

  • 45

    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–1583

  • 46

    Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastasis. Ann Surg 2010; 252: 426–433.

  • 47

    Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, Moral A, Ballester B, Vidal S: Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol 2013; 20: 120–127

  • 48

    Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U; International Breast Cancer Study Group Trial 23-01 investigators: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297–305

  • 49

    Cserni G, Bezsenyi I, Markó L: Patients’ choice on axillary lymph node dissection following sentinel lymph node micrometastasis – First report on prospective use of a nomogram in very low risk patients. Pathol Oncol Res 2013; 19: 211–216

  • 50

    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members: Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206–2223

  • 51

    Lázár Gy, Besznyák I, Boross G, Farsang Z, Gulyás G, Jakab F, Maráz R, Márkus B, Tóth L: Az emlőrák korszerű sebészi kezelése – II. Konszenzuskonferencia. Magy Seb 2010; 63: 132–140

  • 52

    Lázár Gy, Besznyák I, Boross G, Farsang Z, Gulyás G, Jakab F, Maráz R, Márkus B, Tóth L: Az emlőrák korszerű sebészi kezelése. Magy Onkol 2010; 54: 227–234

  • 53

    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575

  • 54

    Gatzemeier W, Mann GB: Which sentinel-node positive breast cancer patients need an axillary lymph-node dissection – ACOSOG Z0011 results and beyond. Breast 2013; 22: 211–216

  • 55

    Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buchholz TA, Giuliano A, Haffty BG: Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol 2014; 32: 3600–3606

  • 56

    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15: 1303–1310

  • 57

    Sávolt A, Musonda P, Mátrai Z, Polgár C, Rényi-Vámos F, Rubovszky G, Kovács E, Sinkovics I, Udvarhelyi N, Török K, Kásler M, Péley G: Az axilla optimális kezelése pozitív őrszemnyirokcsomó esetén korai invazív emlőrákban. Az OTOASOR vizsgálat előzetes eredményei. Orv Hetil 2013; 154: 1934–1942

  • 58

    Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ: Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010; 28: 731–737

  • 59

    Sávolt A, Polgár C, Musonda P, Mátrai Z, Rényi-Vámos F, Tóth L, Kásler M, Péley G: Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients? Clin Breast Cancer 2013; 13: 364–370

  • 60

    Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ: Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009, 27: 2946–2953

  • 61

    Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members: Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533–1546

  • 62

    National Institute for Health and Care Excellence, Centre for Clinical Practice Surveillance Programme: https://www.nice.org.uk/proxy/?sourceUrl=http%3A%2F%2Fwww.nice.org.uk%2Fnicemedia%2Flive%2F10887%2F70385%2F70385.pdf; [December 2014] Accessed: 4 October 2015

  • 63

    Goyal A, Dodwell D: POSNOC: A randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol (R Coll Radiol) 2015; 27(12): 692–695

  • 64

    Gentilini O, Veronesi U: Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast 2012; 21: 678–681

  • 65

    Cserni G: How much is enough? Pathologic evaluation of sentinel lymph nodes. Current Breast Cancer Reports 2012; 4: 89–95

Submit Your Manuscript

 

The author instruction is available in PDF.
Please, download the file from HERE

 

Senior editors

Editor(s)-in-Chief: Oláh, Attila

Editorial Board

  • DR. BÁLINT ANDRÁS
  • DR. BEZSILLA JÁNOS
  • DR. BOROS MIHÁLY
  • DR. BURSICS ATTILA
  • DR. DAMJANOVICH LÁSZLÓ
  • DR. ENTZ LÁSZLÓ
  • DR. GULYÁS GUSZTÁV
  • DR. HARSÁNYI LÁSZLÓ
  • DR. HORVÁTH ÖRS PÉTER
  • DR. ISTVÁN GÁBOR
  • DR. KECSKÉS LÁSZLÓ
  • DR. KÓBORI LÁSZLÓ
  • DR. KUPCSULIK PÉTER
  • DR. LÁZÁR GYÖRGY
  • DR. LESTÁR BÉLA
  • DR. MÁTRAI ZOLTÁN
  • DR. MOHOS ELEMÉR
  • DR. MOLNÁR F. TAMÁS
  • DR. ONDREJKA PÁL
  • DR. PAPP ANDRÁS
  • DR. RÉNYI-VÁMOS FERENC
  • DR. ROMICS LÁSZLÓ JR.
  • DR. SÓTONYI PÉTER
  • DR. SZIJÁRTÓ ATTILA
  • DR. SZŰCS ÁKOS
  • DR. VEREBÉLY TIBOR
  • DR. VERECZKEI ANDRÁS

Petz Aladár County Teaching Hospital, Surgery
Vasvári Pál út 2. H-9024 Győr, Hungary
Phone: +36 96 503 320 --- Fax: +36 96 507 936
E-mail: olaha@petz.gyor.hu

Indexing and Abstracting Services:

  • Index Medicus
  • PubMed Central

 

2020  
CrossRef Documents 37
WoS Cites 45
Wos H-index 8
Days from submission to acceptance 60
Days from acceptance to publication 63

 

2019  
WoS
Cites
63
CrossRef
Documents
31

 

Magyar Sebészet
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Printed Color Illustrations 40 EUR (or 10 000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 276 EUR / 372 USD
Print + online subscription: 320 EUR / 400 USD
Subscription fee 2022 Online subsscription: 282 EUR / 380 USD
Print + online subscription: 328 EUR / 450 USD
Subscription Information

Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.

Purchase per Title Individual articles are sold on the displayed price.

Magyar Sebészet
Language Hungarian
Size B5
Year of
Foundation
1947
Publication
Programme
2021 Volume 74
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Sebész Társaság -- Hungarian Surgical Society
Founder's
Address
H-1082 Budapest, Hungary Üllői út 78.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0295 (Print)
ISSN 1789-4301 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 6 0 0
May 2021 10 1 1
Jun 2021 14 0 0
Jul 2021 4 0 0
Aug 2021 26 0 0
Sep 2021 9 0 0
Oct 2021 0 0 0